Insulet Co. (NASDAQ:PODD) Shares Sold by Graham Capital Management L.P.

Graham Capital Management L.P. decreased its holdings in Insulet Co. (NASDAQ:PODD) by 4.5% in the fourth quarter, Holdings Channel reports. The fund owned 10,893 shares of the medical instruments supplier’s stock after selling 513 shares during the period. Graham Capital Management L.P.’s holdings in Insulet were worth $2,844,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new stake in shares of Insulet in the fourth quarter valued at approximately $36,000. Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in Insulet by 30.1% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier’s stock worth $2,192,000 after buying an additional 1,942 shares during the last quarter. Ayrshire Capital Management LLC grew its holdings in Insulet by 34.6% in the 4th quarter. Ayrshire Capital Management LLC now owns 22,988 shares of the medical instruments supplier’s stock valued at $6,001,000 after buying an additional 5,911 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Insulet by 21.8% in the 4th quarter. Jennison Associates LLC now owns 158,342 shares of the medical instruments supplier’s stock worth $41,338,000 after acquiring an additional 28,375 shares during the last quarter. Finally, USA Financial Formulas purchased a new position in shares of Insulet during the 4th quarter worth $1,234,000.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PODD shares. Royal Bank of Canada started coverage on shares of Insulet in a report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price objective for the company. Raymond James reissued an “outperform” rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Oppenheimer lifted their price target on shares of Insulet from $312.00 to $324.00 and gave the company an “outperform” rating in a research report on Friday. Stifel Nicolaus increased their price objective on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Finally, Piper Sandler lifted their target price on Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $303.81.

Insider Activity at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares in the company, valued at $888,525. The trade was a 36.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.47% of the stock is currently owned by company insiders.

Insulet Stock Up 20.8 %

Shares of PODD opened at $310.42 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market capitalization of $21.84 billion, a PE ratio of 53.61, a P/E/G ratio of 3.62 and a beta of 1.26. The company’s 50-day simple moving average is $257.45 and its 200-day simple moving average is $263.70. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $312.16.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $569.00 million during the quarter, compared to analysts’ expectations of $543.20 million. During the same quarter last year, the company posted $0.73 EPS. The firm’s revenue was up 28.8% compared to the same quarter last year. Analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.